HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss

HighField Biopharmaceuticals2 other diseases, said naturally occurred diabetic monkeys experienced weight loss and HbA1c level reduction during an assessment period of two months following a single injection with HFG1.